GADD45B Facilitates Metastasis of Ovarian Cancer Through Epithelial–Mesenchymal Transition

References

• Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. The Lancet. 2014;384(9951):1376–1388.
   PubMed Web of Science ®Google Scholar
• Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. The Lancet. 2018.
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Torre LA, Trabert B, DeSantis CE, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018;68(4):284–296.
   PubMed Web of Science ®Google Scholar
• Bowtell DD, Böhm S, Ahmed AA, et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer. 2015;15(11):668–679.
   PubMed Web of Science ®Google Scholar
• Weidle UH, Birzele F, Kollmorgen G, Rueger R. Mechanisms and targets involved in dissemination of ovarian cancer. Cancer Genomics Proteomics. 2016;13(6):407–423.
   PubMed Web of Science ®Google Scholar
• Liebermann DA, Tront JS, Sha X, Mukherjee K, Mohamed-Hadley A, Hoffman B. Gadd45 stress sensors in malignancy and leukemia. Crit Rev Oncog. 2011;16(1–2):129–140.
   PubMedGoogle Scholar
• Takekawa M, Saito H. A family of stress-inducible GADD45-like proteins mediate activation of the stress-responsive MTK1/MEKK4 MAPKKK. Cell. 1998;95(4):521–530.
   PubMed Web of Science ®Google Scholar
• Kigar SL, Chang L, Auger AP. Gadd45b is an epigenetic regulator of juvenile social behavior and alters local pro-inflammatory cytokine production in the rodent amygdala. Brain Behav Immun. 2015;46:60–69.
   PubMed Web of Science ®Google Scholar
• Zhao Z, Gao Y. GADD45B as a prognostic and predictive biomarker in Stage II colorectal cancer. 2018;9:7.
   Google Scholar
• Barros-Filho MC, de Mello JBH, Marchi FA, et al. GADD45B transcript is a prognostic marker in papillary thyroid carcinoma patients treated with total thyroidectomy and radioiodine therapy. Front Endocrinol (Lausanne). 2020;11:269.
   PubMed Web of Science ®Google Scholar
• Inowa T, Hishikawa K, Matsuzaki Y, et al. GADD45β determines chemoresistance and invasive growth of side population cells of human embryonic carcinoma. Stem Cells Int. 2010;2010:782967.
   PubMed Web of Science ®Google Scholar
• Myint KZ, Kongpracha P, Rattanasinganchan P, et al. Gadd45β silencing impaired viability and metastatic phenotypes in cholangiocarcinoma cells by modulating the EMT pathway. Oncol Lett. 2018;15(3):3031–3041.
   PubMed Web of Science ®Google Scholar
• Li L, Cai S, Liu S, Feng H, Zhang J. Bioinformatics analysis to screen the key prognostic genes in ovarian cancer. J Ovarian Res. 2017;10(1):27.
   PubMedGoogle Scholar
• Lu X, Lu J, Liao B, Li X, Qian X. Driver pattern identification over the gene co-expression of drug response in ovarian cancer by integrating high throughput genomics data. 2017;7(1):16188.
   Google Scholar
• Verzella D, Bennett J, Fischietti M, et al. GADD45β loss ablates innate immunosuppression in cancer. Cancer Res. 2018;78(5):1275–1292.
   PubMed Web of Science ®Google Scholar
• Pils D, Hager G, Tong D, et al. Validating the impact of a molecular subtype in ovarian cancer on outcomes: a study of the OVCAD Consortium. Cancer Sci. 2012;103(7):1334–1341.
   PubMed Web of Science ®Google Scholar
• Gyorffy B, Lánczky A, Szállási Z. Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. Endocr Relat Cancer. 2012;19(2):197–208.
   PubMed Web of Science ®Google Scholar
• Guo J, Cai J, Zhang Y, Zhu Y, Yang P, Wang Z. Establishment of two ovarian cancer orthotopic xenograft mouse models for in vivo imaging: a comparative study. Int J Oncol. 2017;51(4):1199–1208.
   PubMed Web of Science ®Google Scholar
• Takekawa M, Saito HA. Family of Stress-Inducible GADD45-like proteins mediate activation of the stress-responsive MTK1/MEKK4 MAPKKK. Cell. 1998;95(4):521–530.
   PubMed Web of Science ®Google Scholar
• Sha X, Hoffman B, Liebermann DA. Loss of Gadd45b accelerates BCR-ABL-driven CML. Oncotarget. 9(70):33360–33367.
   PubMedGoogle Scholar
• Michaelis KA, Knox AJ, Xu M, et al. Identification of growth arrest and DNA-damage-inducible Gene β (GADD45β) as a novel tumor suppressor in pituitary gonadotrope tumors. Endocrinology. 2011;152(10):3603–3613.
   PubMed Web of Science ®Google Scholar
• Engelmann A, Speidel D, Bornkamm GW, Deppert W, Stocking C. Gadd45β is a pro-survival factor associated with stress-resistant tumors. Oncogene. 2008;27(10):1429–1438.
   PubMed Web of Science ®Google Scholar
• Dongre A, Weinberg RA. New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol 2019/02/01. 2019;20(2):69–84.
   PubMed Web of Science ®Google Scholar
• Tang XH, Li H, Zheng XS, Lu MS. CRM197 reverses paclitaxel resistance by inhibiting the NAC-1/Gadd45 pathway in paclitaxel-resistant ovarian cancer cells. 2019;8(14):6426–6436.
   Google Scholar
• Yang TC, Wu PC, Chung IF, Jiang JH, Fann MJ, Kao LS. Cell death caused by the synergistic effects of zinc and dopamine is mediated by a stress sensor gene Gadd45b - implication in the pathogenesis of Parkinson’s disease. J Neurochem. 2016;139(1):120–133.
   PubMed Web of Science ®Google Scholar
• Lucas A, Mialet-Perez J, Daviaud D, Parini A, Marber MS, Sicard P. Gadd45γ regulates cardiomyocyte death and post-myocardial infarction left ventricular remodelling. Cardiovasc Res. 2015;108(2):254–267.
   PubMed Web of Science ®Google Scholar
• Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133(4):704–715.
   PubMed Web of Science ®Google Scholar
• Georgakopoulos-Soares I, Chartoumpekis DV, Kyriazopoulou V, Zaravinos A, Factors EMT. Metabolic pathways in cancer. Front Oncol. 2020;10:499.
   PubMed Web of Science ®Google Scholar
• Craene BD, Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer. 2013;13(2):97–110.
   PubMed Web of Science ®Google Scholar
• Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15(3):178–196.
   PubMed Web of Science ®Google Scholar
• De Smaele E, Zazzeroni F, Papa S, et al. Induction of gadd45β by NF-κB downregulates pro-apoptotic JNK signalling. Nature. 2001;414(6861):308–313.
   PubMed Web of Science ®Google Scholar
• Tornatore L, Sandomenico A, Raimondo D, et al. Cancer-selective targeting of the NF-κB survival pathway with GADD45β/MKK7 inhibitors. Cancer Cell. 2014;26(4):495–508.
   PubMed Web of Science ®Google Scholar
• Papa S, Zazzeroni F, Bubici C, et al. Gadd45β mediates the NF-κB suppression of JNK signalling by targeting MKK7/JNKK2. Nat Cell Biol. 2004;6(2):146–153.
   PubMed Web of Science ®Google Scholar
• Kuo CL, Chou HY, Chiu YC, et al. Mitochondrial oxidative stress by Lon-PYCR1 maintains an immunosuppressive tumor microenvironment that promotes cancer progression and metastasis. Cancer Lett. 2020;474:138–150.
   PubMed Web of Science ®Google Scholar
• Xu J, Shi J, Tang W. ROR2 promotes the epithelial-mesenchymal transition by regulating MAPK/p38 signaling pathway in breast cancer. 2020;12.
   Google Scholar
• Olea-Flores M, Zuñiga-Eulogio MD. Extracellular-signal regulated kinase: a central molecule driving epithelial-mesenchymal transition in cancer. 2019;20:12.
   Google Scholar
• Yoo J, Ghiassi M, Jirmanova L, et al. Transforming growth factor-beta-induced apoptosis is mediated by Smad-dependent expression of GADD45b through p38 activation. J Biol Chem. 2003;278(44):43001–43007.
   PubMed Web of Science ®Google Scholar
• Massagué J. TGFbeta in Cancer. Cell. 2008;134(2):215–230.
   PubMed Web of Science ®Google Scholar
• Teixeira AF, Ten Dijke P, Zhu HJ. On-target Anti-TGF-β therapies are not succeeding in clinical cancer treatments: what are remaining challenges? Front cell Develop Biol. 2020;8:605.
   PubMed Web of Science ®Google Scholar
• Roane BM, Arend RC, Birrer MJ. Review: targeting the transforming growth factor-beta pathway in ovarian cancer. Cancers. 2019;11:5.
   Web of Science ®Google Scholar